Sio Capital reports 3.08M shares (5.77%) of PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. Amendment No. 3 to a Schedule 13G/A reports that Sio Capital Management, LLC beneficially owned 3,076,580 shares of common stock, representing 5.77% of the class.

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. Amendment No. 3 to a Schedule 13G/A reports that Sio Capital Management, LLC beneficially owned 3,076,580 shares of common stock, representing 5.77% of the class. The filing states these shares are held with shared voting and dispositive power as of March 31, 2026. The filing cites 53,329,392 shares outstanding as of March 6, 2026 from the issuer's Form 10-K. The statement is signed by the Reporting Person's Chief Compliance Officer on May 4, 2026.

Insights

Institutional Ownership Analyst

Sio holds a meaningful passive stake with shared control over votes and dispositions.

Sio Capital Management, LLC is reported to beneficially own 3,076,580 shares and to exercise shared voting and dispositive power over those shares as of March 31, 2026. The percentage ownership is 5.77%, computed against the issuer's stated outstanding share count of 53,329,392 as of March 6, 2026.

Because the filing is a Schedule 13G/A amendment, it characterizes the holding as passive or reportable under the applicable rules; further changes in ownership or voting arrangements would appear in subsequent beneficial ownership statements.

Compliance / SEC Filings Specialist

The filing clarifies attribution and overlap between Sio, its GP, and a controlling individual.

The statement explains that Sio and Sio GP, LLC act for clients that own the shares and that Michael Castor may be deemed to control voting and dispositive decisions. The filing includes a disclaimer that neither the GP nor Mr. Castor admit beneficial ownership.

For corporate recordkeeping, the disclosed shared voting/dispositive powers and the explicit outstanding-share anchor are the operative facts to track.

Key Figures

Shares beneficially owned: 3,076,580 shares Percent of class: 5.77% Shares outstanding (issuer): 53,329,392 shares

3 metrics

Shares beneficially owned 3,076,580 shares Reported as of March 31, 2026

Percent of class 5.77% Calculated using outstanding shares reported in Form 10-K

Shares outstanding (issuer) 53,329,392 shares Outstanding as of March 6, 2026 per issuer's Form 10-K

Key Terms

Schedule 13G/A, beneficially owned, shared dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 3 to a Schedule 13G/A reports beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"As of March 31, 2026, Sio beneficially owned 3,076,580 shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared dispositive power: 3,076,580 reported in Item 4"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Sio Capital Management hold in PMV Pharmaceuticals (PMVP)?

Sio Capital Management beneficially owns 3,076,580 shares, equal to 5.77% of the class. The filing states this figure as of March 31, 2026, and cites 53,329,392 shares outstanding as of March 6, 2026 from PMV's Form 10-K.

Does Sio have voting control over the PMVP shares it reports?

The filing reports Sio holds shared voting power and shared dispositive power over the 3,076,580 shares. The statement attributes those shared powers to Sio's advisory role for affiliated funds and refers to oversight by the GP.

How is beneficial ownership attributed between Sio, its GP, and Michael Castor?

The schedule explains Sio and Sio GP, LLC act for clients that are record owners, and Michael Castor may be deemed to control decisions. It also states the GP and Mr. Castor expressly disclaim admission of beneficial ownership in the filing.

What dates anchor the ownership and outstanding-share counts in the filing?

Ownership is reported as of March 31, 2026, and the outstanding-share count cited is as of March 6, 2026. The statement was signed on May 4, 2026 by the Reporting Person's Chief Compliance Officer.

Is this filing an acquisition or a passive holdings update?

This is an amendment to a Schedule 13G/A reporting existing beneficial ownership, not an acquisition notice. Schedule 13G filings typically report passive or qualifying institutional holdings rather than active acquisition intent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:14 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, par value $0.00001 per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 69353Y103

1

Names of Reporting Persons

Sio Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,076,580.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,076,580.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,076,580.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.77 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: 1 As of March 31, 2026, Sio Capital Management, LLC beneficially owned 3,076,580 shares of Common Stock with shared voting power and shared dispositive power. 2 Based on 53,329,392 shares of common stock outstanding as of March 6, 2026, as reported in the Issuer's Form 10-K filed with the SEC on March 6, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PMV Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 400 Alexander Park Drive, Suite 301, Princeton, NJ, 08540
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)	Address or principal business office or, if none, residence: 600 Third Avenue, 2nd Floor New York, New York 10016
(c)	Citizenship: Sio is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.00001 per share
(e)	CUSIP No.: 69353Y103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,076,580
(b)	Percent of class: 5.77 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,076,580 - Refer to footnote 3
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,076,580 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sio Capital Management, LLC

Signature:	/s/ Jin W. Lee
Name/Title:	Chief Compliance Officer
Date:	05/04/2026